Cargando…
Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab
BACKGROUND: Atopic dermatitis (AD) is a chronic recurrent inflammatory disease, and dupilumab, a human monoclonal antibody, is the firstly approved biological drug for AD. Psoriasiform erythema (PE) during dupilumab treatment in adults has been reported. This study describes the risk of PE in childr...
Autores principales: | Ali, Kamran, Wu, Liming, Qiu, YunMi, Li, Menghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366075/ https://www.ncbi.nlm.nih.gov/pubmed/35966849 http://dx.doi.org/10.3389/fmed.2022.932766 |
Ejemplares similares
-
Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
por: Shan, Jinpeng, et al.
Publicado: (2022) -
Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis
por: WU, LiMing, et al.
Publicado: (2022) -
Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma
por: QIU, YunMi, et al.
Publicado: (2022) -
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series
por: de Wijs, L.E.M., et al.
Publicado: (2019) -
Dupilumab for atopic dermatitis
Publicado: (2019)